Cytokine gene polymorphisms in chronic hepatitis B: a step up the immunology ladder
dc.contributor.author | Wai, Chun-Tao | en_US |
dc.contributor.author | Fontana, Robert John | en_US |
dc.date.accessioned | 2010-06-01T18:52:33Z | |
dc.date.available | 2010-06-01T18:52:33Z | |
dc.date.issued | 2003-01 | en_US |
dc.identifier.citation | Wai, Chun T . ; Fontana, Robert J . (2003). "Cytokine gene polymorphisms in chronic hepatitis B: a step up the immunology ladder." The American Journal of Gastroenterology 98(1): 6-8. <http://hdl.handle.net/2027.42/72069> | en_US |
dc.identifier.issn | 0002-9270 | en_US |
dc.identifier.issn | 1572-0241 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/72069 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12526929&dopt=citation | en_US |
dc.format.extent | 39426 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2003 by Am. Coll. of Gastroenterology | en_US |
dc.title | Cytokine gene polymorphisms in chronic hepatitis B: a step up the immunology ladder | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gastroenterology University of Michigan Medical School Ann Arbor, Michigan USA | en_US |
dc.identifier.pmid | 12526929 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/72069/1/j.1572-0241.2003.07169.x.pdf | |
dc.identifier.doi | 10.1111/j.1572-0241.2003.07169.x | en_US |
dc.identifier.source | The American Journal of Gastroenterology | en_US |
dc.identifier.citedreference | Mast E.E., Alter M.J., Margolis H.S.. Strategies to prevent and control hepatitis B and C virus infections: A global perspective. Vaccine 1999; 17: 1730 – 1733. | en_US |
dc.identifier.citedreference | Margolis H.S., Alter M.J., Hadler S.C.. Hepatitis B: Evolving epidemiology and implications for control. Semin Liv Dis 1991; 11: 84 – 92. | en_US |
dc.identifier.citedreference | Tassopoulos N.C., Papaevangelou G.J., Sjogren M.H., et al. Natural history of acute hepatitis B surface antigen hepatitis in Greek adults. Gastroenterology 1987; 92: 1844 – 1850. | en_US |
dc.identifier.citedreference | Mayerat C., Mantegani A., Frei P.C.. Does hepatitis B virus genotype influence the clinical outcome of HBV infection?. J Viral Hepatitis 1999; 6: 299 – 304. | en_US |
dc.identifier.citedreference | Webster G.J., Reignat S., Maini M.K., et al. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 2000; 32: 1117 – 1124. | en_US |
dc.identifier.citedreference | Chisari F.V.. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29 – 60. | en_US |
dc.identifier.citedreference | Rehermann B., Ferrari C., Pasquinelli C., Chisari F.V.. The hepatitis B virus persists for decades after patients, recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104 – 1108. | en_US |
dc.identifier.citedreference | Guidotti L.G., Chisari F.V.. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65 – 91. | en_US |
dc.identifier.citedreference | Lohr H., Gerken G., Schlicht H., et al. Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis 1993; 168: 1133 – 1139. | en_US |
dc.identifier.citedreference | Bertoletti A., D’Elios M.M., Boni C., et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193 – 199. | en_US |
dc.identifier.citedreference | Livingston B.D., Alexander J., Crimi C., et al. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol 1999; 162: 3088 – 3095. | en_US |
dc.identifier.citedreference | Thursz M.R., Kwiatkowski D., Alsopp C.E.M., et al. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N Engl J Med 1995; 332: 1065 – 1069. | en_US |
dc.identifier.citedreference | Thursz M.. MHC and the viral hepatitides. Quart J Med 2001; 94: 287 – 291. | en_US |
dc.identifier.citedreference | Ben Ari Z, Mor E, Kfir B, et al. Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 2003; 98: 144 – 150. | en_US |
dc.identifier.citedreference | Bidwell J.L., Wood N.A., Morse H.R., et al. Human cytokine gene nucleotide sequence alignments. Eur J Immunogenet 1998; 25: 83 – 265. | en_US |
dc.identifier.citedreference | Gewaltig J., Mangasser-Stephan K., Gartung C., et al. Association of polymorphisms of the transforming growth factor-B1 gene with the rate of progression of HCV induced liver fibrosis. Clin Chim Acta 2002; 316: 83 – 94. | en_US |
dc.identifier.citedreference | Powell E.E., Edwards-Smith C.J., Hay J.L., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000; 31: 828 – 833. | en_US |
dc.identifier.citedreference | Kohler T., Kruger A., Gerken G., et al. A tumor necrosis factor-alpha (TNFa) promoter polymorphism is associated with chronic hepatitis B. Clin Exp Immunol 1998; 111: 579 – 582. | en_US |
dc.identifier.citedreference | Pravica V., Asderakis A., Perrey C., et al. In vitro production of IFN-Γ correlates with CA repeat polymorphism in the human IFN-Γ gene. Eur J Immunogenet 1999; 26: 1 – 3. | en_US |
dc.identifier.citedreference | DiBisceglie A.M., Rustgi V.K., Kassianides C., et al. Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon. Hepatology 1990; 11: 266 – 270. | en_US |
dc.identifier.citedreference | Boni C., Bertoletti A., Penna A., et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. Br J Clin Invest 1998; 102: 968 – 975. | en_US |
dc.identifier.citedreference | Boni C., Penna A., Ogg G.S., et al. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy. Hepatology 2001; 33: 963 – 971. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.